UOC
RVNC

UBS O'Connor’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS O'Connor’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$48K – 387
2022
Q3 		$48K Hold
100,000
– – ﹤0.01% 862
2022
Q2 		$125K Buy
+100,000
New +$1.54M ﹤0.01% 852

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

UBS O'Connor's RVNC Position: Q3 2024 in Review

UBS O'Connor sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 325,314 shares — an estimated $836K sold.

UBS O'Connor first reported a position in RVNC in Q2 2022 and held it in 7 quarters. The position peaked at $2.73M in Q3 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • UBS O'Connor reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 325,314 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $836K.
  • UBS O'Connor first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 7 quarters.
  • UBS O'Connor's Revance Therapeutics, Inc. position peaked at $2.73M in Q3 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.